Plain-English translation of NCT07092696 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called camrelizumab, which is a type of immunotherapy that helps your immune system fight cancer. You would receive this medication in combination with chemotherapy first, then continue it while undergoing chemotherapy and radiation treatment together. The goal is to see if this approach improves outcomes for women with locally advanced cervical cancer.
Research suggests that giving immunotherapy before radiation may work better than giving it at the same time or after, because radiation can sometimes weaken the immune response. This trial wants to test whether the new sequencing — immunotherapy first, then combined with radiation — offers better results and safety for patients.
You likely qualify if…
You likely don't qualify if…
You would first receive the immunotherapy medication combined with chemotherapy as an induction phase. Then you would receive this medication again while undergoing concurrent chemotherapy and radiation treatment. After completing radiation, you would continue receiving the medication as maintenance therapy. Throughout the trial, you will have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~34 participants
Started
December 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jie Chen
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.